Quick Answer
BIOXYTRAN, INC reported Total Revenue of $191.1 thousand for fiscal year 2017.
BIOXYTRAN, INC — Key Financials by Year
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — | — |
| Net Income | -$2.37M +47.1% |
-$4.47M -81.5% |
-$2.46M +38.9% |
-$4.03M -58.6% |
-$2.54M -36.8% |
-$1.86M -527.0% |
| Diluted EPS | -$0.02 +33.3% |
-$0.03 -50.0% |
-$0.02 | — | — | — |
| Total Assets | $138.7K -0.5% |
$139.4K -62.4% |
$370.9K +211.0% |
$119.3K -63.5% |
$326.4K +48.6% |
$219.6K +503.2% |
| Cash and Equivalents | — | — | — | — | — | — |
| Stockholders Equity | -$1.79M +42.3% |
-$3.10M +5.8% |
-$3.30M -4.4% |
-$3.16M -62.7% |
-$1.94M -142.9% |
-$799.3K -254.7% |
| R&D Expense | $112.3K -90.2% |
$1.15M +17.5% |
$977.8K -51.4% |
$2.01M +269.8% |
$544.5K | — |
| Operating Income | -$2.22M +41.5% |
-$3.80M -78.1% |
-$2.13M +49.4% |
-$4.21M -232.2% |
-$1.27M +22.2% |
-$1.63M -658.4% |
| Gross Profit | — | — | — | — | — | — |
| Shares Outstanding | 86.78M -40.0% |
144.64M +17.4% |
123.25M +11.2% |
110.84M +13.7% |
97.45M +12.7% |
86.48M +1.6% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | June 30, 2018 | $20.3K | -48.5% | +52.5% |
| Net Income | September 30, 2025 | -$282.7K | +27.9% | -897.8% |
| Diluted EPS | September 30, 2025 | $0.00 | — | — |
| Total Assets | September 30, 2025 | $156.3K | -1.7% | +6.0% |
| Cash and Equivalents | September 30, 2017 | $23.4K | +24.9% | +668.8% |
| Stockholders Equity | September 30, 2025 | -$2.90M | -167.8% | -10.2% |
| R&D Expense | June 30, 2025 | $102.5K | — | -70.7% |
| Operating Income | September 30, 2025 | -$496.0K | -43.3% | -121.4% |
| Gross Profit | June 30, 2018 | $12.2K | -39.3% | +730.9% |
| Shares Outstanding | September 30, 2025 | 88.99M | +8.2% | +0.0% |
- BIOXYTRAN, INC reported Total Revenue of $191.1 thousand for fiscal year 2017.
- BIOXYTRAN, INC showed a decrease of -22.5% in Total Revenue compared to the prior fiscal year.
- BIOXYTRAN, INC reported Net Income of -$2.37 million for fiscal year 2024.
- BIOXYTRAN, INC showed an increase of +47.1% in Net Income compared to the prior fiscal year.
- BIOXYTRAN, INC reported Diluted EPS of $0.02 per share (loss) for fiscal year 2024.
- BIOXYTRAN, INC showed an increase of +33.3% in Diluted EPS compared to the prior fiscal year.
- BIOXYTRAN, INC reported Total Assets of $138.7 thousand for fiscal year 2024.
- BIOXYTRAN, INC showed a decrease of -0.5% in Total Assets compared to the prior fiscal year.
- BIOXYTRAN, INC reported Cash and Equivalents of $11.1 thousand for fiscal year 2016.
- BIOXYTRAN, INC showed an increase of +218.6% in Cash and Equivalents compared to the prior fiscal year.
- BIOXYTRAN, INC reported Stockholders Equity of -$1.79 million for fiscal year 2024.
- BIOXYTRAN, INC showed an increase of +42.3% in Stockholders Equity compared to the prior fiscal year.
- BIOXYTRAN, INC reported R&D Expense of $112.3 thousand for fiscal year 2024.
- BIOXYTRAN, INC showed a decrease of -90.2% in R&D Expense compared to the prior fiscal year.
- BIOXYTRAN, INC reported Operating Income of -$2.22 million for fiscal year 2024.
- BIOXYTRAN, INC showed an increase of +41.5% in Operating Income compared to the prior fiscal year.
- BIOXYTRAN, INC reported Gross Profit of $87.1 thousand for fiscal year 2017.
- BIOXYTRAN, INC showed a decrease of -42.0% in Gross Profit compared to the prior fiscal year.
- BIOXYTRAN, INC reported Shares Outstanding of 86.78 million shares for fiscal year 2024.
- BIOXYTRAN, INC showed a decrease of -40.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: